Video

What's Exciting in the Field of MPNs?

Author(s):

Ross L. Levine, M.D.

Ross L. Levine, M.D., physician-scientist, director of the Memorial Sloan Kettering (MSK) Center for Hematologic Malignancies and 2016 MPN Hero, discusses the work at his lab that he is currently excited about.

Ross L. Levine, M.D., physician-scientist, director of the Memorial Sloan Kettering (MSK) Center for Hematologic Malignancies and 2016 MPN Hero, discusses the work at his lab that he is currently excited about.

Levine and his team are turning their focus to the JAK2 gene to build on recent successes in the field and hopefully develop some novel approaches. They are also investigating other possible genetic mutations that can be blocked.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a woman wearing a headband and glasses
Image of man.
Image of doctor.
CURE spoke with Andy Guinigundo to discuss the role that biomarkers play for patients with breast cancer.
Colorectal cancer is on the rise among younger adults, although potential explanations for the cause of this trend are likely years away.
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
Image of doctor.
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
Related Content
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Cancer Horizons podcast logo
January 8th 2024

FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis

Alex Biese Brielle Benyon
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Illustration of blood cells.
March 16th 2025

Jakafi May Not Associate with Long-Term Benefits in Myelofibrosis Subset

Spencer Feldman
Real-world data suggest Jakafi shows limited benefits in CALR-mutated myelofibrosis.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
December 16th 2021

LeVar Burton Helping the MPN Community Through Advocacy and Storytelling

Jamie Cesanek Darlene Dobkowski, MA
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Illustration of blood cells.
March 3rd 2025

Rusfertide Elicits Promising Responses in Polycythemia Vera

Alex Biese
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted in positive responses.
Image of Dr. Fakih.
February 27th 2025

ctDNA Alone ‘Not Sufficient’ When Monitoring Patients With Colorectal Cancer

Dr. Marwan Fakih
The addition of ctDNA testing to radiographic surveillance resulted in curative surgical intervention for 1.6% of patients with colorectal cancer.